03 Sep Nemours Study: Early Opioid Administration For Sickle Cell Children in Crisis Decreased Hospitalization Rate

MedicalResearch.com Interview with:

Dr. Gwarzo

Ibrahim Gwarzo, DrPH, MPH, MBBS
Research Scientist at Nemours Children’s Health
Delaware Valley, Delaware USA

MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of sickle cell disease and why young people frequently present to the ER with severe pain?

Response: Sickle cell disease is an inherited blood disorder that affects red blood cells. It is passed down as an autosomal recessive disorder, meaning a person must inherit the defective gene from both parents to have the disease. The condition primarily impacts hemoglobin, the protein responsible for carrying oxygen in red blood cells, which leads to changes in the shape and stability of these cells. The complications associated with the disease, including recurrent and severe pain episodes, are a direct result of these changes. These pain episodes are debilitating and unpredictable, resulting in frequent emergency department visits where they are typically treated with pain medications, including opioids. It is estimated that around 100,000 people in the United States have sickle cell disease, with about 40,000 being children. The disease has a significant prevalence in the Afro-Latino population.

MedicalResearch.com: What are the main findings of your analysis?

Response:  Our study found that the timely administration of opioid pain medication was associated with a decreased likelihood of hospitalization for children who presented at the emergency department with a sickle cell pain episode. We found that when the first opioid dose was given within one hour of arrival and a subsequent dose was given within a 30-minute interval, the likelihood of hospitalization reduced by up to 38% in these patients. Even though the magnitude was smaller, we also observed a lower likelihood of hospitalization when subsequent opioid doses were delayed beyond 30 minutes but administered within 45 minutes and 60 minutes from the first dose.

MedicalResearch.com: What should readers take away from your report?

Response: We want readers to recognize that these recurrent pain episodes represent a serious complication for patients. Our study highlights that timely administration of opioids is not only humane, but also evidence-based in preventing hospitalizations, reducing costs, and promoting equity.

MedicalResearch.com: What recommendations do you have for future research as a results of this study?

Response: Our multisite approach strengthens generalizability beyond single-center studies, but gaps remain; we used data on pediatric populations only and therefore, do not know if our findings are generalizable to the broader sickle cell population. Future studies should evaluate the impact of timeliness of analgesia delivery in diverse settings, including adults and rural areas, and track metrics like patient satisfaction or 30-day readmissions.

Readers in research or policy should advocate for increased funding and interventions to refine guidelines for managing sickle cell pain.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response: I have no disclosures to make.

I am genuinely grateful for the opportunity to engage in this work. Having personally been affected by this disease and having lost a family member to its complications, I am motivated to help and advocate for these patients in the best way possible. My focus is on conducting research and implementing interventions that aim to enhance the quality of care they receive.

Citation: Gwarzo I, Coleman KD, McKinley K, et al. Opioid Timeliness in the Emergency Department and Hospitalizations for Acute Sickle Cell Pain. JAMA Pediatr. Published online September 02, 2025. doi:10.1001/jamapediatrics.2025.2967

—-

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links may be sponsored. Products are not warranted or endorsed.

Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on September 3, 2025 by Marie Benz MD FAAD